Predicting Adverse Drug Effects from Literature- and Database-Mined Assertions
- 354 Downloads
Given that adverse drug effects (ADEs) have led to post-market patient harm and subsequent drug withdrawal, failure of candidate agents in the drug development process, and other negative outcomes, it is essential to attempt to forecast ADEs and other relevant drug–target–effect relationships as early as possible. Current pharmacologic data sources, providing multiple complementary perspectives on the drug–target–effect paradigm, can be integrated to facilitate the inference of relationships between these entities.
This study aims to identify both existing and unknown relationships between chemicals (C), protein targets (T), and ADEs (E) based on evidence in the literature.
Materials and Methods
Cheminformatics and data mining approaches were employed to integrate and analyze publicly available clinical pharmacology data and literature assertions interrelating drugs, targets, and ADEs. Based on these assertions, a C–T–E relationship knowledge base was developed. Known pairwise relationships between chemicals, targets, and ADEs were collected from several pharmacological and biomedical data sources. These relationships were curated and integrated according to Swanson’s paradigm to form C–T–E triangles. Missing C–E edges were then inferred as C–E relationships.
Unreported associations between drugs, targets, and ADEs were inferred, and inferences were prioritized as testable hypotheses. Several C–E inferences, including testosterone → myocardial infarction, were identified using inferences based on the literature sources published prior to confirmatory case reports. Timestamping approaches confirmed the predictive ability of this inference strategy on a larger scale.
The presented workflow, based on free-access databases and an association-based inference scheme, provided novel C–E relationships that have been validated post hoc in case reports. With refinement of prioritization schemes for the generated C–E inferences, this workflow may provide an effective computational method for the early detection of potential drug candidate ADEs that can be followed by targeted experimental investigations.
The authors would like to thank Mr Alexander Gartland for fruitful discussions that helped to improve the quality of the manuscript.
The MedDRA® trademark is owned by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on behalf of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).
Compliance with Ethical Standards
This study was supported in part by the National Institutes of Health (Grant 1U01CA207160).
Conflict of interest
Mary La, Alexander Sedykh, Denis Fourches, Eugene Muratov, and Alexander Tropsha declare no conflict of interests that are directly relevant to the content of this study.
- 4.Agency for Healthcare Research and Quality. Reducing and preventing adverse drug events to decrease hospital costs. AHRQ Archive. https://archive.ahrq.gov/research/findings/factsheets/errors-safety/aderia/ade.html. Accessed 2 Apr 2014.
- 5.Ninan B, Wertheimer A. Withdrawing drugs in the U.S. versus other countries. Innov Pharm. 2012;3(3):Article 87. https://pubs.lib.umn.edu/index.php/innovations/article/view/269/263. Accessed 19 Apr 2018.
- 8.US Food and Drug Administration. openFDA datasets: FAERS. https://open.fda.gov/data/faers/. Accessed 19 Apr 2018.
- 28.Lo HZ, Ding W, Nazeri Z. Mining adverse drug reactions from electronic health records. In: 2013 IEEE 13th Int Conf Data Min Workshop. 2013. p. 1137–40.Google Scholar
- 31.Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, et al. The NCGC Pharmaceutical Collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011;3:80ps16. https://tripod.nih.gov/npc/. Accessed 23 May 2018.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.National Library of Medicine. Unified Medical Language System (UMLS). 2013. https://www.nlm.nih.gov/research/umls/. Accessed 2 Mar 2015.
- 43.MedDRA. 2013. https://www.meddra.org/. Accessed 19 Apr 2018.
- 45.Cover TM, Thomas JA. Relative entropy and mutual information. In: Elements of information theory. 2nd ed. New York: Wiley Interscience; 2006. p. 19–20.Google Scholar
- 51.Metjian A, Abrams CS. New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents. Biol Targets Ther. 2009;3:499–513.Google Scholar
- 58.US Food and Drug Administration, Center for Drug Evaluation and Research. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. 2015. https://www.fda.gov/Drugs/DrugSafety/ucm436259.htm. Accessed 19 Apr 2018.